Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2026 09:00 ET | Source: Human Continuum Inc.

Human Continuum Appoints Dr. Michael Milligan, MD, MBA, as its Chief Medical Officer to Oversee Innovative Applications for Next-Generation Extracellular Vesicle Therapeutics

New York, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced...
February 24, 2026 07:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in...
February 23, 2026 08:00 ET | Source: Alps Group Inc

Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol

KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated...
February 23, 2026 08:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Participation in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor...
February 20, 2026 07:16 ET | Source: Research and Markets

State of the Life Sciences Industry, Q4 2025 Review - Unveils Key Trends and Opportunities in Pharma, Biopharma, Medical Devices, Cell Biology

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "State of the Life Sciences Industry - Fourth Quarter Review" has been added to ResearchAndMarkets.com's offering. The latest quarterly research...
February 19, 2026 07:22 ET | Source: Research and Markets

$19.8 Billion Cell and Gene Therapy Tools & Reagents Market Outlook, 2030 Featuring Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, Sartorius and More

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools and Reagents: Global Markets" has been added to ResearchAndMarkets.com's offering.The global market for cell and gene...
February 18, 2026 11:26 ET | Source: Research and Markets

Bio/Pharmaceutical Outsourcing Report December 2025: Trump Administration Sets Deadline for Pharma Companies to Fulfill MFN Commitments/UK-US Tariff Deal and Pricing Reforms Position UK As Global Hub

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Bio/Pharmaceutical Outsourcing Report, December 2025" report has been added to ResearchAndMarkets.com's offering.The Bio/Pharmaceutical Outsourcing...
February 18, 2026 11:04 ET | Source: Research and Markets

CAR T - Cell Therapy Competitive Landscape Research Report 2026: Comprehensive Insights About 250+ Companies and 500+ Drugs - Key Opportunities Lie in Targeting Hematologic Malignancies

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "CAR T - Cell Therapy - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. This report offers a comprehensive...
February 13, 2026 16:30 ET | Source: Longeveron

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Longeveron (LGVN) has appointed Stephen H. Willard as Chief Executive Officer.
February 12, 2026 07:30 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell...